Audentes Therapeutics appointed Edward R. Conner, M.D. as Senior Vice President and Chief Medical Officer and promoted Fulvio Mavilio, Ph.D. to Senior Vice President of Translational Science.
Audentes Therapeutics has commenced dosing of patients in ASPIRO, a Phase 1/2 clinical trial of AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM).